Skip to main content

Advertisement

Table 5 NCCR analysis in samples collected from Crohn’s Disease and Multiple Sclerosis patients

From: Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study

A. Crohn’s Disease patients
Samples N° JCPyV positive samples N° archetype* (%) (IIS) 37 T→G and 217 G→A** (IIS) N° rearranged NCCR sequences (%)
37 T→G , 217 G→A** and boxD deletion (IIR) Mad1-like sequence (IR)
Urine 34 34 (100%) 0 0 0
Plasma 28 20 (71%) 8 (29%) 0 0
Ileum 21 10 (47%) 7 (33%) 4 (20%) 0
Colon-rectum 16 8 (50%) 5 (32%) 1 (6%) 2 (12%)
Total (%) 99 72 (72%) 20 (21%) 5 (5%) 2 (2%)
B. Multiple Sclerosis patients
Samples N° JCPyV positive samples N° archetype* (%) (IIS) N° rearranged NCCR sequences (%)
duplication of a 98bp unit and 66bp insert (boxD)(IIR)
Urine 13 13 (100%) 0
Plasma 7 7 (100%) 0
PBMC 3 1 (33%) 2 (67%)
Total (%) 23 21 (91%) 2 (9%)
  1. * JCPyV archetype CY[38] with random occurrence of few point mutations and constant G to A transition at position nucleotide number 217 in the boxF.
  2. ** T to G transversion at position nucleotide number 37 in the box A within Spi-B binding site, and G to A transition at position nucleotide number 217 in the boxF considering the nucleotide numbering based on non-pathogenic JCPyV archetype CY[38].
  3. † Jensen and Major (2001) NCCR forms classification is also reported[35].